Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Cash from Investing Activities (2023 - 2025)

Historic Cash from Investing Activities for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $38.1 million.

  • Monte Rosa Therapeutics' Cash from Investing Activities rose 103.05% to $38.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$67.7 million, marking a year-over-year decrease of 923130.9%. This contributed to the annual value of -$44.5 million for FY2024, which is 15005.8% down from last year.
  • Latest data reveals that Monte Rosa Therapeutics reported Cash from Investing Activities of $38.1 million as of Q3 2025, which was up 103.05% from $25.3 million recorded in Q2 2025.
  • In the past 5 years, Monte Rosa Therapeutics' Cash from Investing Activities ranged from a high of $38.1 million in Q3 2025 and a low of -$100.2 million during Q1 2025
  • For the 3-year period, Monte Rosa Therapeutics' Cash from Investing Activities averaged around $689272.7, with its median value being $18.6 million (2023).
  • The largest annual percentage gain for Monte Rosa Therapeutics' Cash from Investing Activities in the last 5 years was 14140.75% (2025), contrasted with its biggest fall of 111724.35% (2025).
  • Over the past 3 years, Monte Rosa Therapeutics' Cash from Investing Activities (Quarter) stood at $14.3 million in 2023, then crashed by 316.1% to -$30.9 million in 2024, then surged by 223.44% to $38.1 million in 2025.
  • Its Cash from Investing Activities stands at $38.1 million for Q3 2025, versus $25.3 million for Q2 2025 and -$100.2 million for Q1 2025.